Randomized, placebo-controlled, double-blind study to evaluate the efficacy of 2LHERP® in patients with recurrent orofacial herpes infections.

You likely can't join if

• - Pregnant or breastfeeding woman, - Patient under immunotherapy (including immunosuppressive treatment) or microimmunotherapy received during last previous 6 months, - Patient who had a suppressive antiviral therapy during last month, - Patient who wishes to continue his/her suppressive antiviral therapy, - Patient with known lactose intolerance, galactose intolerance, lactase Lapp deficiency or glucose-galactose malabsorption syndrome - Patient who participated in a clinical study in the previous 3-month period, - Patient who is not sufficiently motivated to engage in a follow-up period of 12 months, or likely to travel or to move before the end of the study, - Patient with severe immunodeficiency disease requiring long term treatment (*) or under chemotherapy or radiotherapy or corticoid therapy, - Patient under listed homeopathic or phytotherapy treatment, - Patient using or addicted to recreational drugs. (*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV/AIDS, terminal cancer.